CHOSA announces a new collaboration with lung cancer experts paving the way for integration into clinical guidelines
This partnership leverages existing high-quality clinical data permitting efficacy prediction of cisplatin and carboplatin in patients with advanced lung cancer
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
10Th, February 2025,– CHOSA announces a collaboration with international lung cancer experts utilizing clinical data already obtained in a large clinical study. In the SPLENDOUR trial, more than 500 patients with advanced lung cancer received platinum-based therapy. Tumor samples from the study are available for platinum sensitivity analysis. These will allow CHOSA to utilize biopsies from an already performed high-quality study, and in a very cost-effective way obtain useful clinical data aimed to pave the way to commercialization. Platinum drugs are used in almost all medical treatments of lung cancer and CHOSA will determine the Cisplatin-DRP accuracy in the prediction of tumor response to cisplatin or carboplatin chemotherapy. The study is expected to give pivotal data on the way for CHOSA’s test in clinical guidelines and regulatory approval.
The study will be done in collaboration with the ETOP IBCSG Partners Foundation and the European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial lung cancer experts, Professor Solange Peters and Professor Rolf Stahel. CHOSA will perform the analyses at Allarity’s laboratories.
The SPLENDOUR trial is described at https://pubmed.ncbi.nlm.nih.gov/32565388/
“Platinum-compounds are widely used in the treatment of non-small cell lung cancer and combined with new immunotherapies, are highly effective. However, as of today there are no biomarkers allowing to predict their efficacy or toxicity. We at ETOP IBCSG Partners Foundation are happy to collaborate with CHOSA to develop such a platinum biomarker.” Said Professors Solange Peters and Rolf Stahel.
“Lung cancer is far too often a lethal disease. This project aimed at paving the Cisplatin-Drug Response Predictor (Cisplatin-DRP) as a tool to enhance treatment outcomes for patients with stage IV non-small cell lung cancer (NSCLC). Said CEO, MD, DMSc Peter Buhl Jensen. "Lung cancer treatment prediction is a critical clinical need. Partnering with top lung cancer experts from ETOP is a major milestone for CHOSA. This collaboration grants us access to high-quality biopsies from a top-tier clinical study we couldn't conduct ourselves. It saves us years of work and significantly reduces costs" Buhl Jensen further commented.
Background
Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer chemotherapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD-1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Cisplatin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer.
This study will explore the predictive potential of the Cisplatin-DRP not only in cisplatin-treated patients but also in those treated with carboplatin. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort, potentially confirming its utility across both drugs. Future research will aim to determine whether the Cisplatin-DRP can predict the effectiveness of combinations of platinum drugs with PD-1/L1 inhibitors.
About ETOP IBCSG Partners Foundation
The ETOP IBCSG Partners Foundation is a not-for-profit international academic research organization based in Berne, Switzerland. Established on July 1, 2021, through the merger of the European Thoracic Oncology Platform (ETOP) and the International Breast Cancer Study Group (IBCSG), the foundation aims to promote scientific exchange and advance cancer research, particularly in thoracic and breast cancers.
The foundation's mission is to answer questions that improve patients' lives, with a vision of enhancing scientific exchange on a global scale. It achieves this by implementing and promoting clinical and translational research studies, fostering collaboration among international investigators, and organizing educational events such as annual meetings and residential workshops.
For additional information, contact:
Peter Buhl Jensen, CEO
Peter@chosa.bio
+ 45 21 60 89 22
CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of LiPlaCis® and the DRP®.
About Cisplatin-DRP, a test to predict if cisplatin treatment is likely to be successful
CHOSA is focused on late-stage clinical development of LiPlaCis® and its DRP® drug response predictor to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment.
Lung: The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer, especially in new neoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with cisplatin doubles. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.
Immunotherapy There is a new development that adds further value to our DRP. Cisplatin has often been shown to activate the immune system (making cold tumors hot), which makes tumors susceptible to PD1 inhibitors. This synergy is particularly important but not limited to the treatment of lung cancer, bladder cancer, and head and neck cancer. In the ever-growing PD1 inhibitor market, where competition is fierce, our company stands out with the ability to predict if cisplatin will provide synergy with PD1. This can give the PD1 selling companies a significant competitive advantage.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.